TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31292177

Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration of corticosteroids and anaesthetic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration with inflammation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-articular infiltration without inflammation
Number of subjects: 0
Study: 31292728

Group type: EXPERIMENTAL
Intervention: Turkish version of the Mastication Observation and Evaluation (T-MOE) instrument
Number of subjects: 80

Group type: COMPARATOR
Intervention: Typical children without chewing disorders
Number of subjects: 80
Study: 31292901

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) treatment for 14 days
Number of subjects: 24
Study: 31293437

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31294009

Group type: EXPERIMENTAL
Intervention: Therapeutic ballet intervention
Number of subjects: 0
Study: 31294762

Group type: EXPERIMENTAL
Intervention: Pembrolizumab therapy (200 mg every 21 days for 8 cycles, with provision to continue to 16 cycles)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pembrolizumab therapy
Number of subjects: 51
Study: 31295674

Group type: EXPERIMENTAL
Intervention: mepolizumab (a humanized monoclonal antibody to IL-5), administered for 52 weeks
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 610
Study: 31296082

Group type: EXPERIMENTAL
Intervention: MANTA vascular closure device (14F used in 42 cases, 18F used in 221 cases)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: MANTA vascular closure device
Number of subjects: 341
Study: 31296099

Group type: EXPERIMENTAL
Intervention: Higher levels of Cer-16
Number of subjects: 4249

Group type: EXPERIMENTAL
Intervention: Higher levels of SM-16
Number of subjects: 4249

Group type: EXPERIMENTAL
Intervention: Higher levels of Cer-22
Number of subjects: 4249

Group type: EXPERIMENTAL
Intervention: Higher levels of SM-20
Number of subjects: 4249

Group type: EXPERIMENTAL
Intervention: Higher levels of SM-22
Number of subjects: 4249

Group type: EXPERIMENTAL
Intervention: Higher levels of SM-24
Number of subjects: 4249
Study: 31296225

Group type: EXPERIMENTAL
Intervention: TyG index (calculated using Ln(fasting triglycerides (mg/dl) × fasting blood glucose (mg/dl)/2))
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Higher carbohydrate consumption and lower lipid consumption
Number of subjects: 2330
Study: 31296423

Group type: EXPERIMENTAL
Intervention: Lenalidomide (20 mg) plus obinutuzumab (1000 mg) as induction therapy for six 28-day cycles.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg) plus obinutuzumab (1000 mg) for 1-year maintenance (12 28-day cycles; days 2-22) and obinutuzumab (1000 mg) for 1-year maintenance (six 56-day cycles; day 1).
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Induction therapy with lenalidomide plus obinutuzumab.
Number of subjects: 89
Study: 31296643

Group type: EXPERIMENTAL
Intervention: Vegetable intake
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Fruit intake
Number of subjects: 472
Study: 31296923

Group type: COMPARATOR
Intervention: Post-operative CEA ≤ 2.35 ng/mL
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Post-operative CEA > 2.35 ng/mL
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Addition of oxaliplatin to adjuvant treatment
Number of subjects: 899
Study: 31296992

Group type: EXPERIMENTAL
Intervention: AOM 400 (aripiprazole once-monthly 400 mg)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 31297046

Group type: EXPERIMENTAL
Intervention: Hypnotic Suggestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial Direct-Current Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31297231

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 14 days
Number of subjects: 651

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 651
Study: 31297236

Group type: EXPERIMENTAL
Intervention: REACH lifestyle intervention
Number of subjects: 10
Study: 31297636

Group type: EXPERIMENTAL
Intervention: PF-04136309 (CCR2 inhibitor) plus nab-paclitaxel (125 mg/m2) and gemcitabine
Number of subjects: 0
Study: 31297647

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (HT) with aromatase inhibitors
Number of subjects: 39
Study: 31297671

Group type: EXPERIMENTAL
Intervention: Full-automated 3D-TEE measurements
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Semi-automated 3D-TEE measurements
Number of subjects: 67

Group type: COMPARATOR
Intervention: Semi-automated THV sizing
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intra-class correlation coefficients of semi-automated method
Number of subjects: 67
Study: 31297947

Group type: EXPERIMENTAL
Intervention: Second-line therapy combinations of metformin with DPP-4 inhibitors
Number of subjects: 14668

Group type: EXPERIMENTAL
Intervention: Second-line therapy combinations of metformin with sulphonylureas
Number of subjects: 14668

Group type: EXPERIMENTAL
Intervention: Second-line therapy combinations of metformin with sodium-glucose co-transporter-2 inhibitors
Number of subjects: 14668

Group type: EXPERIMENTAL
Intervention: Second-line therapy combinations of metformin with glucagon-like peptide-1 receptor agonists
Number of subjects: 14668

Group type: COMPARATOR
Intervention: First-line metformin monotherapy
Number of subjects: 14668

Group type: COMPARATOR
Intervention: Socioeconomic status
Number of subjects: 14668
Study: 31298221

Group type: EXPERIMENTAL
Intervention: iBall intervention group (n=13)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study: 31298286

Group type: EXPERIMENTAL
Intervention: Standardized 6-day low-sodium diet to stimulate RAAS activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAAS activation
Number of subjects: 0
Study: 31298497

Group type: EXPERIMENTAL
Intervention: Feminizing hormone therapy (E2 valerate and cyproterone acetate) prescribed at baseline until week 5, and then from week 8 until the end of study.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine initiated at week 3 and continued without interruption.
Number of subjects: 20
Study: 31298551

Group type: EXPERIMENTAL
Intervention: ESC 0/1-hour algorithm
Number of subjects: 2525

Group type: COMPARATOR
Intervention: ESC 0/3-hour protocol
Number of subjects: 2525
Study: 31298706

Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-exendin-4 PET/CT plus MRI
Number of subjects: 6

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 6

Group type: COMPARATOR
Intervention: 68Ga-DOTA-exendin-4 PET/CT
Number of subjects: 6
Study: 31298972

Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox
Number of subjects: 0
Study: 31299005

Group type: EXPERIMENTAL
Intervention: M6620 (ATR inhibitor) and cisplatin
Number of subjects: 1
Study: 31299007

Group type: EXPERIMENTAL
Intervention: Serial measurement of optic nerve sheath diameter (ONSD) during therapy for DKA.
Number of subjects: 0
Study: 31299074

Group type: EXPERIMENTAL
Intervention: efavirenz-based ART (600 mg daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: nevirapine-based ART (200 mg twice daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (not receiving ART)
Number of subjects: 57
Study: 31299246

Group type: EXPERIMENTAL
Intervention: sirolimus and hydroxychloroquine
Number of subjects: 0
Study: 31299468

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FSC) treatment
Number of subjects: 2005
Study: 31299650

Group type: EXPERIMENTAL
Intervention: Clazosentan administration
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control group (no clazosentan)
Number of subjects: 413
Study: 31299906

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 13638
Study: 31299966

Group type: EXPERIMENTAL
Intervention: Cancer care coordination nursing occupations (complex intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theoretical reference framework for care coordination in France
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-depth analysis of practices, contexts, perceptions, and attitudes related to care coordination occupations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typology of nurse practices in cancer care coordination
Number of subjects: 0
Study: 31299972

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) diagnosed with eGFR < 60 mL/min/1.73m²
Number of subjects: 2274
Study: 31299988

Group type: EXPERIMENTAL
Intervention: Surgery (abdominal procedures)
Number of subjects: 15
Study: 31300344

Group type: EXPERIMENTAL
Intervention: MGN1703 (TLR9 agonist) for 24 weeks
Number of subjects: 7
Study: 31300360

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg daily
Number of subjects: 73
Study: 31300502

Group type: EXPERIMENTAL
Intervention: Continuously-Employed group
Number of subjects: 193

Group type: COMPARATOR
Intervention: Employed-Unemployed group
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Characteristics associated with return to work
Number of subjects: 193
Study: 31300820

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SIMPLIFY) for 12 weeks
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir/dasabuvir/ombitasvir ± ribavirin (D3FEAT) for 12 weeks
Number of subjects: 190
Study: 31300969

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: ACEIs/ARBs
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 361
Study: 31300973

Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFIRI
Number of subjects: 69
Study: 31300979

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 677
Study: 31301122

Group type: EXPERIMENTAL
Intervention: Capsinoid ingestion and cold exposure
Number of subjects: 20
Study: 31301251

Group type: EXPERIMENTAL
Intervention: PCOS-HS index (including BMI percentile, waist circumference, ALT, and SHBG)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Validation cohort of PCOS-HS index
Number of subjects: 108
Study: 31301430

Group type: EXPERIMENTAL
Intervention: Radiographically normal knees with contralateral joint space narrowing (JSN)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bilaterally normal knees (KLG0)
Number of subjects: 120
Study: 31301853

Group type: EXPERIMENTAL
Intervention: Total Sarnat score of ≥5 performed at <6 hours of age
Number of subjects: 0
Study: 31301920

Group type: EXPERIMENTAL
Intervention: Zoster vaccine live (ZVL)
Number of subjects: 1500000
Study: 31301962

Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg + Pembrolizumab 200 mg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 mg/kg + Pembrolizumab 200 mg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ramucirumab + Pembrolizumab
Number of subjects: 92
Study: 31302044

Group type: EXPERIMENTAL
Intervention: Plasma eicosapentaenoic acid (EPA) abundance (%EPA) measured at baseline
Number of subjects: 6562
Study: 31302344

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (CTx) with TS-1 (35 mg/m²) for two 21-day courses followed by chemoradiotherapy (CCRT)
Number of subjects: 42
Study: 31302639

Group type: EXPERIMENTAL
Intervention: Severe aortic stenosis management
Number of subjects: 2171
Study: 31302640

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine via ultrasound-guided nerve stimulator-assisted subgluteal sciatic nerve block
Number of subjects: 86
Study: 31303133

Group type: EXPERIMENTAL
Intervention: Double-layer carotid stents
Number of subjects: 0
Study: 31303142

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus rilpivirine
Number of subjects: 0
Study: 31303143

Group type: EXPERIMENTAL
Intervention: Guideline concordant care for long-term opioid therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31303280

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing salmon's milt extract, 1 capsule per day for the first 4 weeks, then 1 capsule in the morning and 1 capsule in the evening for the remaining 8 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing salmon's milt extract
Number of subjects: 87

Group type: COMPARATOR
Intervention: Healthy controls (n = 20; 15 women, 5 men; age range 25-65 years)
Number of subjects: 87
Study: 31303316

Group type: EXPERIMENTAL
Intervention: Arginine-stimulated copeptin measurements
Number of subjects: 98
Study: 31303427

Group type: EXPERIMENTAL
Intervention: McArdle sign (greater than 10% neck flexion-induced reduction in strength)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Clinical and quantitative measures of McArdle sign
Number of subjects: 106

Group type: COMPARATOR
Intervention: Receiver operating characteristic curve
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Correlation of McArdle sign measurements
Number of subjects: 106
Study: 31303457

Group type: EXPERIMENTAL
Intervention: Blood count control (≥1 controlled blood count)
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: Blood count control (≥2 controlled blood counts)
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: Complete hematologic remission (CHR)
Number of subjects: 1714

Group type: COMPARATOR
Intervention: No blood count control
Number of subjects: 1714
Study: 31303642

Group type: EXPERIMENTAL
Intervention: DigniCap® scalp-cooling system
Number of subjects: 139
Study: 31303643

Group type: EXPERIMENTAL
Intervention: CFI-400945 at 64 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CFI-400945 at 96 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CFI-400945 at 72 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CFI-400945 at 3 to 96 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CFI-400945
Number of subjects: 43
Study: 31304019

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome and smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infertile men
Number of subjects: 0
Study: 31304320

Group type: EXPERIMENTAL
Intervention: AI-based diagnostic system
Number of subjects: 900

Group type: COMPARATOR
Intervention: Wisconsin Fundus Photograph Reading Center (FPRC) widefield stereoscopic photography and macular Optical Coherence Tomography (OCT)
Number of subjects: 900
Study: 31304365

Group type: EXPERIMENTAL
Intervention: Add-on modelling datasets (experimental group)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Conventional diagnostic parameters (control group)
Number of subjects: 178
Study: 31304455

Group type: EXPERIMENTAL
Intervention: Sun exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin reflectance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adiposity
Number of subjects: 0
Study: 31304801

Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Number of subjects: 0
Study: 31304973

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Recovery sleep
Number of subjects: 31

Group type: COMPARATOR
Intervention: Baseline (8 hours of wakefulness)
Number of subjects: 31
Study: 31305924

Group type: EXPERIMENTAL
Intervention: GH (Norditropin) prescribed according to local practice
Number of subjects: 19847
Study: 31306033

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31306183

Group type: EXPERIMENTAL
Intervention: 3D-CAM
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control (DSM-5 reference standard)
Number of subjects: 176
Study: 31306318

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 1295
Study: 31306555

Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg once daily for 4 weeks, with dose adjustments thereafter
Number of subjects: 28
Study: 31306621

Group type: EXPERIMENTAL
Intervention: Prior acute coronary syndromes
Number of subjects: 39679

Group type: COMPARATOR
Intervention: OAC ± AP therapy
Number of subjects: 39679

Group type: EXPERIMENTAL
Intervention: AP therapy
Number of subjects: 39679

Group type: EXPERIMENTAL
Intervention: Dual AP therapy
Number of subjects: 39679

Group type: COMPARATOR
Intervention: OAC with or without AP therapy
Number of subjects: 39679
Study: 31307216

Group type: EXPERIMENTAL
Intervention: Maternal DENV neutralizing antibodies
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: DENV-4 neutralizing antibody
Number of subjects: 139
Study: 31307393

Group type: EXPERIMENTAL
Intervention: Preventive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cox Proportional Hazard (Cox-PH) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generalized Additive Model (GAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cox-SPDE model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPDE models
Number of subjects: 0
Study: 31307443

Group type: EXPERIMENTAL
Intervention: French version of the Nursing Home Survey on Patient Safety Culture (NHSOPS) questionnaire
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: French version of the NHSOPS questionnaire
Number of subjects: 61
Study: 31307482

Group type: EXPERIMENTAL
Intervention: Vitamin D deficient (<50 nmol/L)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficient (50-75 nmol/L)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Vitamin D replete (>75 nmol/L)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Adjusted live birth rates for vitamin D deficient
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Adjusted live birth rates for vitamin D insufficient
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Adjusted live birth rates for vitamin D replete
Number of subjects: 500
Study: 31307502

Group type: EXPERIMENTAL
Intervention: Expedition: Strategic Advantage (active program)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Expedition: Informational Advantage (control program)
Number of subjects: 100
Study: 31307542

Group type: EXPERIMENTAL
Intervention: Clinical diagnostic criteria (Amsterdam II criteria and revised Bethesda guidelines)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: IHC of MMR proteins
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: MSI test
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Combined IHC and MSI test
Number of subjects: 111
Study: 31307859

Group type: EXPERIMENTAL
Intervention: PMD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCZ
Number of subjects: 0

Group type: COMPARATOR
Intervention: HC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 0
Study: 31308059

Group type: EXPERIMENTAL
Intervention: CDX-3379 (1,000 mg) administered as two infusions at a 2-week interval
Number of subjects: 12
Study: 31308197

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 141
Study: 31308835

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (6-day once-daily administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linezolid (10-day twice-daily administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 0
Study: 31308926

Group type: EXPERIMENTAL
Intervention: Patients with HFpEF and T2D
Number of subjects: 140

Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 140
Study: 31309541

Group type: EXPERIMENTAL
Intervention: Oral CHOP-like chemotherapy
Number of subjects: 0
Study: 31309911

Group type: EXPERIMENTAL
Intervention: Ponderal index at birth in infertile women
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ponderal index at birth in fertile women
Number of subjects: 125
Study: 31310310

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) therapy for 8 years
Number of subjects: 24
Study: 31310353

Group type: EXPERIMENTAL
Intervention: Development and implementation of a transmural care pathway for self-management support.
Number of subjects: 0
Study: 31310994

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Teens with obesity
Number of subjects: 930

Group type: COMPARATOR
Intervention: Boys
Number of subjects: 930

Group type: COMPARATOR
Intervention: Sundays
Number of subjects: 930

Group type: COMPARATOR
Intervention: Weekend sedentary time
Number of subjects: 930
Study: 31311438

Group type: EXPERIMENTAL
Intervention: Takotsubo Syndrome patients with malignancy
Number of subjects: 1604

Group type: COMPARATOR
Intervention: Takotsubo Syndrome patients without malignancy
Number of subjects: 1604
Study: 31311545

Group type: EXPERIMENTAL
Intervention: PCO-VP
Number of subjects: 126
Study: 31311763

Group type: EXPERIMENTAL
Intervention: Radium-223, 55 kBq/kg, every 4 weeks for ≤6 cycles
Number of subjects: 696
Study: 31311898

Group type: EXPERIMENTAL
Intervention: Polypharmacy (defined as the use of 5 or more medications at one time)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Drug-drug interactions (DDIs) determined using the Lexicomp Online drug interaction screening tool
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications defined based on the 2015 update of the Beers Criteria
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Severity of comorbid disease recorded and scored according to Charlson Comorbidity Index (CCI)
Number of subjects: 5000
Study: 31312030

Group type: EXPERIMENTAL
Intervention: Binimetinib and capecitabine (DL3 dose level)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Binimetinib and capecitabine (DL3 dose level) in patients with RAS/RAF/MEK/ERK pathway mutations
Number of subjects: 34
Study: 31312170

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31312536

Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab (NIVO + IPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab monotherapy (NIVO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab monotherapy (IPI)
Number of subjects: 0
Study: 31312806

Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccinations (8-week interval)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccinations (24-week interval)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ChAdV63.MVA/HIVconsv vaccination
Number of subjects: 24
Study: 31313237

Group type: EXPERIMENTAL
Intervention: Exercise group (EG)
Number of subjects: 23